Showing results (261-270 of 319) with videos related to

Sort By:
Pageof 32
Drug Research|February 4, 2017
Is the Inhibition of Dipeptidyl Peptidase-4 (DDP-4) Enzyme Route Dependent and/or Driven by High Peak Concentration?- Seeking Answers with ZYDPLA1, a Novel Long Acting DPP-4 Inhibitor, in a Rodent ModelHarilal Patel, Amit A Joharapurkar, Rajesh Bahekar, et al.
ACS Medicinal Chemistry Letters|June 6, 2014
Cobicistat (GS-9350): A Potent and Selective Inhibitor of Human CYP3A as a Novel PharmacoenhancerLianhong Xu, Hongtao Liu, Bernard P Murray, et al.
Asian Journal of Urology|April 29, 2024
Metabolic syndrome and the urinary microbiome of patients undergoing percutaneous nephrolithotomyRyan A Dornbier, Chirag P Doshi, Shalin C Desai, et al.
Bioorganic & Medicinal Chemistry Letters|April 13, 2019
Discovery of 1,3-dihydro-2H-imidazo[4,5-c]quinolin-2-ones based novel, potent and PI3Kδ selective inhibitorsRajesh Bahekar, Bhushan Dave, Shubhangi Soman, et al.
Separation and Purification Technology|May 29, 2026
Separation of intrinsically magnetic cells using magnetic filtersJacob Strayer, Hyeon Choe, Xian Wu, et al.
Bioorganic & Medicinal Chemistry Letters|December 4, 2014
Gastric-sparing nitric oxide-releasable 'true' prodrugs of aspirin and naproxenMachhindra Gund, Parikshit Gaikwad, Namdev Borhade, et al.
Journal of Clinical Gastroenterology|August 19, 2010
Is gastroduodenal biopsy safe in patients receiving aspirin and clopidogrel?: a prospective, randomized study involving 630 biopsiesMatthew J Whitson, Andrew E Dikman, Caroline von Althann, et al.
Investigative and Clinical Urology|May 20, 2016
Electronic nutritional intake assessment in patients with urolithiasis: A decision impact analysisAvory M Heningburg, Anand Mohapatra, Aaron M Potretzke, et al.
Bioorganic & Medicinal Chemistry Letters|December 31, 2005
Design and synthesis of potent and subtype-selective PPARalpha agonistsRanjit C Desai, Edward Metzger, Conrad Santini, et al.
The Journal of Pharmacology and Experimental Therapeutics|March 30, 2025
Discovery of ZYDG2: A potent, selective, and safe GPR40 agonist for treatment of type 2 diabetesMukul R Jain, Suresh R Giri, Chitrang J Trivedi, et al.
Pageof 32